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ABSTRACT
Purpose To generate and characterize a specific monoclonal
antibody (mAb) against recombinant human RANK receptor
and to develop an antiresorptive strategy using this mAb as an
osteoclast-targeting platform that selectively targets osteoclast
cells whilst delivering an attached (i.e. chemically conjugated)
active drug cargo.
Methods Using hybridoma technology, we generated a
specific monoclonal antibody (mAb) against recombinant
human RANK receptor and characterized by SDS PAGE,
ELISA, Western Blot and immunocytochemistry, then
synthesized osteoclast-targeting bioconjugates of salmon
calcitonin (sCT) using this antibody by generating thiol
groups on mAb using 2-Iminothiolane and subsequently
reacting them with sCT-PEG-MAL synthesised from sCTand
NHS-PEG-MAL. To test the efficacy of the conjugate in
vitro, osteoclasts were generated from precursor RAW
264.7 cells by dosing with the cytokines macrophage-
colony-stimulating factor (M-CSF), and RANK Ligand
(RANKL) and TRAP activity assay, Resorption Pit Assay,
TRAP staining were performed. Cytotoxicity of the mAb-
sCTconjugate was also evaluated in RAW 264.7 cells; sCT
bioactivity and CTR binding potential were evaluated by in
vitro intracellular cAMP stimulation assay in human T47D
breast cancer cells.
Results Generation of antibody against human RANK recep-
tor was confirmed by SDS PAGE, ELISA and Western Blot.
Immunocytochemistry confirmed the osteoclast targeting
potential of the antibody. Successful conjugation of the
antibody with sCT was confirmed by SDS PAGE and ELISA.
Multinucleated osteoclast formation was confirmed by
staining for tartrate-resistant acid phosphatase (TRAP).
Conjugate functionality was confirmed by TRAP activity and
Resorption Pit assay, showing the inhibitory effect on
osteoclast differentiation. cAMP assay confirmed the reten-
tion of calcitonin bioactivity after conjugation.
Conclusions Our strategy offers the potential for a “universal”
osteoclast-targeting platform—one that targets the RANK
receptor on osteoclast cells by simply altering the conjugated





Osteoclasts are the cells uniquely responsible for dissolving
both the organic and inorganic components of bone during
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throughout life. These cells originate from hematopoietic
precursors of the monocyte/macrophage lineage that are
present both in the bone marrow and peripheral circula-
tion, and their numbers and/or activity are frequently
increased in a wide range of clinical disorders that are
associated with excessive bone loss and which affect millions
of people (1).
Osteoporosis is a major metabolic bone disease that
predisposes patients to fracture in up to 40% of aging
women and 15% of aging men (2). The increase in bone
resorption is due both to increased osteoclastogenesis and to
decreased osteoclast apoptosis (2,3). Osteoclasts may also
play a role in the etiology of post-traumatic osteoarthritis
(PTOA), the most common form of arthritis. At an early
stage of disease pathogenesis, there is a phase of
increased bone resorption and turnover in periarticular
subchondral bone volume and an increased number of
osteoclasts, prior to later stage sclerosis and eburnation
(4). Similarly, increased osteoclast functional activity is
directly responsible for the generalized bone loss that
occurs in rheumatoid arthritis (5). Thus, we hypothesized
that an antiresorptive strategy that selectively targets
osteoclasts and/or carries an active drug to osteoclast
cells directly would be highly desirable as a therapeutic to
treat bone disease involving upregulated osteoclast
activity.
Osteoclast cells express the RANK receptor (receptor
activator of nuclear factor Kappa B) and in effect serve as
ideal molecular targets. RANK is expressed on osteoclast
precursors as well as mature osteoclasts. RANK is the
essential signaling receptor for osteoclast differentiation
during the process of osteoclastogenesis, as triggered by
the osteoclast differentiation factor known as RANK-ligand
(RANKL) (6,7). RANK signaling, with additional signaling
through c-Fms, the receptor for macrophage-colony-stimu-
lating factor (M-CSF), triggers the proliferation and fusion of
mononuclear cells and the formation of multinucleated,
mature osteoclasts (7,8).
Mature osteoclasts will also express the calcitonin
receptor upon its surface, which has been known for
decades as a prominent negative controller of bone
resorption (9). Calcitonin receptors are of the G protein-
coupled receptor family (comprising seven transmembrane-
spanning receptor domains) whose signaling will inhibit
osteoclast activity both in vitro and in vivo (10). Calcitonin
receptor activation upon osteoclasts, by its ligand calcitonin,
will rapidly induce the loss of ruffled border and immobility
followed by cell retraction and arrest of bone resorption.
Calcitonin receptor signaling will also alter ion transporter
distribution, impair enzyme activity (11) and inhibit the
osteoclastogenic effects of RANKL (12).
Since antibodies have exquisite specificity of target
recognition and, thus, generate highly selective outcomes
following their systemic administration, our purpose was to
develop a “universal” osteoclast-targeting platform as a
drug-delivery strategy in order to deliver antiresorptive
drugs using an anti-RANK mAb capable of localizing to
t h ec e l l sr e s p o n s i b l ef o rb o n er e s o r p t i o n .W eh a v e
chosen salmon calcitonin as a model drug, as it acts on
the calcitonin receptor also found on bone-resorbing
osteoclasts.
MATERIALS AND METHODS
Preparation of Anti-RANK Monoclonal Hybridoma
Cell Lines
Monoclonal antibody (mAb) to the RANK receptor was
generated using Hybridoma technology, as previously
performed in our laboratory (13,14). Briefly, 6–8-week-old
female BALB/c mice were immunized intraperitoneally
three times with 25 μg of recombinant human sRANK
receptor (Peprotech, USA) on days 0 and 14 using complete
and incomplete Freund’s adjuvant, respectively, and once
with 10 μg of antigen on day 28 using phosphate-buffered
saline (PBS, pH 7.3). The immune response to the antigen
was assessed by measuring the titer of polyclonal antibody
in mouse serum using an indirect enzyme-linked immuno-
sorbent assay (ELISA). Mice with the highest antibody titer
were euthanized and splenectomized 3 days after the final
injection of antigen. Spleen cells were fused with SP2/0
myeloma cells at a ratio of 4:1 using 50% (w/v)
polyethylene glycol (PEG) (Sigma, USA) according to the
technique described previously by Köhler & Milstein (15).
The hybridoma cells were suspended in culture medium
(RPMI 1640) supplemented with penicillin, streptomycin,
L-glutamine (PSG), hypoxanthine aminopterin thymidine
(HAT), and 20% fetal bovine serum (FBS) (Sigma, USA).
Cells were seeded in 96-well tissue culture plates and
incubated in a humidified 37°C, 5% carbon dioxide
incubator for 2 weeks. Clones were maintained in HAT
medium for a further 2 weeks.
Hybridoma cell lines were screened by an indirect
ELISA. The cell lines producing specific antibodies were
recloned successively 3–7 times by limiting dilution to
ensure monoclonality and stability of the cell line.
Hybridoma cell lines were then propagated in large
175 cm
2 tissue culture flasks, and the conditioned
supernatant collected. Purification of IgG mAbs was
achieved by affinity chromatography using Protein G
agarose (Sigma, USA). The IgG immunoglobulin subclass
was determined using the mouse hybridoma isotyping
1132 Newa et al.reagents according to instructions from the manufacturer
(Sigma, USA).
Indirect Enzyme-Linked Immunosorbent Assay
(ELISA)
All ELISAs were performed in flat-bottomed 96-well plates
(Nunc-Immuno MaxisorbTM plates, Nunc). Antibody
secretion by hybridoma cells was detected by indirect
ELISA. Briefly, 100 μl of antigen (human sRANK receptor)
was used for coating at a concentration of 1 μg/100 μl,
overnight at 4°C. The wells were washed three times with
PBS (pH 7.3) and, to avoid nonspecific binding, incubated
with 3% BSA for 1 h at room temperature. After washing,
the wells were incubated with 100 μl supernatant from each
hybridoma clone for 1 h at room temperature. After
washing, bound antibodies were detected using secondary
goat anti-mouse IgG conjugated with horseradish peroxi-
dase (GAM-HRPO) at a 1:5000 dilution for 1 h at room
temperature. After final washing, 100 μlo f3 , 3 ′,5,5′-
tetramethylbenzidine (TMB substrate) was added to each
well and incubated for 15 min at room temperature. The
optical density (OD) was measured at 650 nm using an
ELISA Vmax kinetic microplate reader (Molecular Devices
Corp., California, USA). The clones showing ELISA values
five times higher than the negative control were considered
positive. Sera of unimmunized mice and irrelevant anti-
body were used as negative controls. RPMI media and
positive sera from hyperimmunized mice were used as
blank and positive control, respectively.
Characterization of Anti-RANK Monoclonal
Antibodies
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) was performed on purified antibody under
both reducing and non-reducing conditions. Antibody was
mixed with loading buffer and run in 10% polyacryl-
amide gel, with the thiol reagent 2-Mercaptoethanol
added to the loading buffer for reducing conditions (to
cleave the disulfide bonds between the polypeptides).
Gels were stained with Coomassie blue for protein band
detection of individual heavy and light chains of the
antibody.
ELISA was performed as above, using 100 μl RANK
receptor for coating at a concentration of 1 μg/100 μl,
overnight at 4°C. To avoid nonspecific binding, the wells
were incubated with 3% BSA for 1 h at room temperature.
After washing, the wells were incubated with different
concentrations of antibody for 1 h. The wells were washed
with PBS, and the bound antibodies were detected using
secondary antibody (goat anti-mouse IgG conjugated
with horseradish peroxidase) for 1 h. After final washing,
100 μl of TMB substrate was added to each well and
incubated for 15 min. The optical density (OD) was
measured at 650 nm.
For Western blot analysis, RANK receptor (19.3 kDa)
was electrophoresed on SDS-PAGE using 10% acrylam-
ide gel and transferred onto nitrocellulose membrane
using mini trans-blot apparatus. The membrane was
b l o c k e dw i t h5 %s k i mm i l ki nP B S - Tf o r1h ,w a s h e d
with PBS-T, cut into strips, and incubated with purified
mAb solution for 1 h. After washing, strips were reacted
with GAM-HRPO for 1 h, and the binding of mAbs to
RANK receptor was detected using enhanced chemilu-
m i n e s c e n c e .F o rt h en e g a t i v ec o n t r o l ,t h ep r i m a r y
antibody was omitted, and the antigen strip incubated
with PBS.
Immunocytochemistry
To confirm the RANK receptor targeting potential of
generated mAb in vitro, osteoclast-like cells were generated
in Lab Tek II chamber slide system (Nunc) from RAW
264.7 cells, as described below for generation of osteoclasts.
The MG-63 osteoblast-like cell line known to lack RANK
receptor (16) was used as negative control. Likewise,
osteoclast cell culture omitting primary mAb was also used
as a method negative control. Cell cultures were washed
with PBS, fixed in 4% paraformaldehyde in PBS (pH 7.4)
for 5 min and rinsed thoroughly. After blocking with 3%
BSA in PBS for 1 h, the cells were incubated with our anti-
RANK mAb (4 μg/ml) overnight at 4°C. Antibody
detection was carried out using rabbit anti-mouse IgG-
FITC (1:100; Sigma, USA) for 60 min at 4°C. To visualize
cell nuclei, slides were counterstained with 1.5 μg/ml 4-6-
diamidino-2 phenylindole (DAPI, Sigma) diluted in PBS.
Culture slides were separated from their chambers,
mounted and photographed using confocal microscopy
(Zeiss LSM 710 with ZEN software and the microscope
the Observer.Z1).
Synthesis of Anti-RANK mAb-Calcitonin Conjugate
Thiolation of Antibodies Using Traut’s Reagent
In order to generate anti-RANK mAb-salmon calcitonin
conjugate (mAb-sCT), free thiol groups were generated on
our anti-RANK mAb by reacting it in a 10 molar excess of
Traut’s reagent at room temperature for 1.5 h (Fig. 1a).
Traut’s reagent (2-Iminothiolane or 2-IT, Sigma USA), a
cyclic thioimidate compound, reacts spontaneously and
efficiently with primary amines at pH 7–9 resulting in
sulfhydryl addition (17,18). No free sulfhydryl moieties were
Universal Osteoclast Drug Targeting Platform 1133found to be present in our IgG mAb, as determined by
Ellman’s assay (19).
Synthesis of Thiol-Reactive Calcitonin Analogue
To generate thiol-reactive calcitonin analogue, synthetic
salmon calcitonin (sCT, Calbiochem, USA) in DMSO
(13.72 mg/ml) was mixed with NHS-PEG-MAL (Creative
Biochem, USA) in DMSO (51 mg/ml) (Sigma,USA) in 1:3
molar ratio. DMSO was chosen as the reaction medium
because of the instability of NHS and sCT in aqueous
solutions. sCT is further highly soluble and highly stable in
DMSO (20). The reaction between the primary amines in
sCT and NHS group of NHS-PEG-MAL was allowed to
proceed at room temperature with constant stirring for
45 min. sCT has three primary amines at residues Lys 11,
Lys 18 and the N-terminus, which can react with the NHS
functional group of NHS-PEG-MAL to generate three
intermediate conjugates: mono-, di- and tri-substituted thiol




Fig. 1 (a) Thiolation of antibodies using Traut’s reagent. (b) Synthesis of thiol reactive sCTanalogue by reacting sCTwith NHS-PEG-MAL. c Coupling free
thiol containing mAb with functionalized thiol reactive sCTanalogue.
1134 Newa et al.Coupling Free Thiol-Containing mAb with Functionalized
Thiol-Reactive sCT Analogue
Functionalized thiol-reactive sCT analogue was added
intermittently with constant stirring to thiol-mAb solution
at 10:1 molar ratio, and the reaction between the thiol-
reactive MAL groups in functionalized sCT and SH group
of thiol-mAb was allowed to proceed at room temperature
in the dark with constant stirring for 2 h. Unreacted sCT-
PEG was removed by dialysis at 4°C (Fig. 1c).
Characterization of Anti-RANK mAb-sCT Conjugate
Anti-RANK mAb-sCT conjugate was examined under
both reducing and non-reducing conditions of SDS-
PAGE analysis, as described above. ELISA was per-
formed, using 100 μl RANK receptor for coating at a
concentration of 1 μg/100 μl ,o v e r n i g h ta t4 ° C .T o
avoid nonspecific binding, the wells were incubated with
3% BSA for 1 h at room temperature. The wells were
incubated in triplicate with either mAb alone, function-
alized sCT-PEG, or mAb-sCT conjugate for 1 h. The
wells were washed with PBST followed by incubation
with rabbit anti-salmon calcitonin antibody (US Bio-
logicals) for 1 h. The wells were washed with PBST three
times and incubated with HRPO conjugated goat anti-
rabbit IgG (R&D Systems) for 1 h. After final washing
with PBST, TMB substrate was added to each well, and
t h eO Dm e a s u r e da t6 5 0n m .
In Vitro Testing of mAb-sCT Conjugate Efficacy
Generation of Osteoclasts
Osteoclast-like cells were generated in culture from RAW
264.7 cells (transformed murine monocytic cell line),
purchased from the American type culture collection
(ATCC, VA, USA) (21). RAW 264.7 cells were cultured
to confluence in a 75 cm
2 flask in GIBCO High Glucose
1X Dulbecco’s Modified Eagle Medium (DMEM, Invitro-
gen, CA, USA) containing 4.5 g/L D-Glucose, L-
glutamine, and 110 mg/L sodium pyruvate, with the
addition of 10% heat-inactivated fetal bovine serum (FBS)
and 1% penicillin-streptomycin added (10,000 U/mL;
Invitrogen, USA). Confluent cells were harvested by
scraping, centrifuged at 1,500 RPM, and resuspended in
25 mL of culture medium. The number of cells in the
suspension was measured using a Bright-Line Hemocytom-
eter (Hausser Scientific, PA, USA) and seeded at a
concentration of 2×10
3cells/well in 96-well culture plates
(Corning) and placed in the CO2 incubator overnight to
allow the cells to attach to the surface. After 24 h, the
culture medium was replaced with media containing
25 ng/ml macrophage-colony-stimulating factor (M-CSF)
and 50 ng/mL RANKL (PeproTech, NJ, USA). Osteo-
clasts were successfully generated by dosing with M-CSF
and RANKL every 48 h over the course of 7 days. To
confirm the generation of multinucleated osteoclast-like
cells, the cultured cells were stained for the enzyme
tartrate-resistant acid phosphatase (TRAP) using the
Leukocyte Acid Phosphatase TRAP Kit from Sigma-
Aldrich (St.Louis, MO, USA), according to the manu-
facturer’s instructions. TRAP-positive multinucleated
osteoclasts were visualized by light microscopy and
photographed.
Spectrophotometric Assay of In Vitro TRAP Activity
To quantify the total TRAP activity from in vitro osteoclast
cultures, RAW264.7 cells were seeded at a concentration of
2×10
3cells/well in 96-well culture plates and incubated for
24 h. Peptide factors 50 ng/ml RANKL and MCSF
25 ng/ml were added to the culture, with or without the
addition of 100 nM of mAb, 100 nM of mAb-sCT, or
100 nM of sCT. The medium and factors were replaced
every 48 h. Osteoclastogenesis was assessed by the
spectrophotometric measurement of TRAP activity on
day 7. Briefly, the medium was aspirated, and the cell
monolayer washed twice with PBS. The cells were then
l y s e dw i t h1 0 0μl of 0.2% Triton X-100 in water (v/v)
for 10 min. TRAP activity in the cell lysate was
determined using an Acid Phosphatase Assay Kit (Cayman
chemical, USA). The assay utilizes para-nitrophenyl
phosphate (pNPP) as a chromogenic substrate for the
TRAP enzyme. In the first step, acid phosphatase
dephosphorylates pNPP. L-tartrate, an inhibitor of non-
tartrate resistant acid phosphatase, provided in the kit
was used to measure TRAP enzyme activity. In the
second step, the phenolic OH- group was deprotonated
under alkaline conditions, resulting in p-nitrophenolate
that yields an intense yellow color, which was measured
a t4 0 5n mu s i n gam i c r o p l a t er e a d e r .
In Vitro Mineral Resorption Assay
To quantify the mineral resorptive activity of osteoclast-like
cells in culture, RAW264.7 cells were suspended in cell
culture medium and seeded in a 16-well BD Biosciences
Osteologic® Slide (BD Biosciences, MA, USA) at the
density of 2×10
3 cells/well and incubated for 24 h.
Osteoclast-like cells were successfully generated by dosing
with 50 ng/ml RANKL and 25 ng/ml M-CSF every 48 h
over the course of 7 days. The wells were incubated with
100 nM of either mAb alone, sCT alone, or mAb-sCT
conjugate. Half the volume of the medium and factors
were replaced every 48 h. After 7 days of culture, the
Universal Osteoclast Drug Targeting Platform 1135medium was aspirated, the slide placed in a petri-dish
and washed with double-distilled water. To remove the
a d h e r e n tc e l l s ,t h es l i d ew a st h e ns o a k e di nb l e a c hf o r
10 min and washed with double-distilled water. Slides
were air-dried, viewed under an inverted light micro-
scope, and low power images of the calcium phosphate
mineral remaining on the slide acquired. To quantify the
resorptive effect of osteoclasts, the images were analyzed
using the javabased image-processing program ImageJ
(NIH, USA).
Cytotoxicity Test for mAb-sCT Conjugate
To ensure that the mAb-sCT conjugate was not cytotoxic
to cells other than osteoclasts, we employed the MTT assay,
in which mitochondrial dehydrogenases of viable cells
cleave the tetrazolium ring of MTT, yielding purple
formazan crystals. An increase or decrease in cell number
results in a concomitant change in the amount of formazan
formed, indicating the degree of cytotoxicity caused by the
test material.
RAW 264.7 cells were seeded on 96-well plates at an
initial density of 2×10
3 cells/well and incubated for 72 h at
37°C, 5% CO2 until the cells were 80% confluent. The
culture medium was replaced by 200 μl basic DMEM
media without FBS and incubated for 30 min. Then the
culture medium was replaced by 100 μl basic DMEM
media containing 50, 100 and 200 nM of mAb, mAb-sCT
and sCT, respectively (in quadruplicate). The cells were
incubated for 4 h at 37°C. The medium was then replaced
with 100 μl basic medium containing (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide) (MTT) at a concen-
tration of 100 μg/well and incubated for a further 4 h at
37°C. After removing the supernatant and washing twice
with phosphate-buffered saline, the newly formed purple
formazan crystals were dissolved in 200 μl solubilization
solution using an in vitro toxicology assay kit (TOX-1,
Sigma Aldrich, St. Louis, USA), and the absorbance was
measured at 570 nm using a microplate reader.
In Vitro Bioactivity of mAb-sCTand Calcitonin Receptor Binding
Affinity
To confirm that calcitonin bioactivity was not lost after
conjugation to mAb and to confirm the ability for mAb-
sCT conjugate to trigger the calcitonin receptor, T47D
human breast cancer cells (known to contain calcitonin
receptors) were used, as previously described (22). Briefly,
T47D cells (ATCC, VA, USA) were cultured in triplicate in
RPMI-1,640 culture medium containing 1% penicillin-
streptomycin, 10% fetal bovine serum, and insulin (0.2 IU/
mL). Cells were seeded on 48-well plates at an initial density
of 5×10
4 cells/well and incubated in 95% air and 5% CO2 at
37°C for 2 days. Cells were then washed with HBSS and pre-
incubated in RPMI-1640 culture medium devoid of FBS,
insulin and antibiotics. Cells were dosed with the phosphodi-
esterase inhibitor, 3-isobutyl-1-methyl-xanthine (IBMX,
1 mM) and incubated at 37°C for 30 min. One
hundred nM of mAb, mAb- sCT and sCT were then added
to the wells except the control where T47D cells were treated
withIBMXonly.Theplatewasincubatedfor20minat37°C.
After removing the supernatant, cells were washed three
times in cold phosphate-buffered saline and resuspended in
500 μl of cell lysis buffer. Cells were frozen at −20°C and
thawed with gentle mixing. The freeze/thaw cycle was
repeated three times, and the mixture was centrifuged at
600 g for 10 min at 2–8°C to remove cellular debris. The
supernatant was collected and stored at −20°C. cAMP
concentrations were then measured using the cyclic
adenosine monophosphate (cAMP) Enzyme Immuno-
Assay (EIA) kit (KGE002B, R & D systems, USA).
STATISTICAL ANALYSIS
Statistical analysis was conducted using Graph Pad Prism 5
(GraphPad Software Inc., CA). Results are presented as the
mean ± standard deviation of three samples. Unpaired
t-tests were used to assign significance between groups,
with a P-value of less than 0.05 as the threshold for
significance. Two-way ANOVA was used for the MTT assay.
RESULTS
SDS-PAGE Analysis
A band at 150 kDa was seen for unconjugated anti-RANK
IgG, with separate bands for heavy chain at 50 kDa and
light chain at 25 kDa observed under reducing condition.
For mAb-sCT conjugate, a band above 150 kDa was
observed, confirming the conjugation to have taken place.
Under reducing condition of SDS-PAGE for conjugate,
some bands above 50 kDa and 25 kDa were observed,
suggestive of conjugation of PEGylated calcitonin to the
heavy and light chains of the antibody. (Fig. 2)
ELISA
The optical density was seen to linearly increase with the
concentration of mAb (Fig. 3a). Spectrophotometric absor-
bance value for 0.25, 0.5, 1.0, 2.0 and 4.0 μg of the anti-
RANK antibody was 0.025, 0.070, 0.131, 0.27 and 0.518,
respectively.
1136 Newa et al.ELISA carried out for the conjugate showed the
binding of the conjugated antibody to the coated RANK
receptor. The sCT attached to the conjugate was
detected using an anti-calcitonin antibody, thus confirm-
ing the intactness of mAb-sCT conjugates. Optical
density for mAb alone was negligible, as it did not have
calcitonin to be detected by anti-calcitonin antibody.
Similarly, OD for sCT-PEG was also significantly low, as
it did not have the anti-RANK mAb targeting moiety
necessary to bind to the RANK coated plate (Fig. 3b).
ELISA-derived spectrophotometric absorbance values for
mAb, sCT-PEG and mAb-sCT conjugate were 0.002,
0.025 and 0.153, respectively.
Western Blot Analysis
Recombinant human sRANK receptor is a 19.3 kDa
polypeptide. It was electrophoresed on a 10% polyacryl-
amide gel and transferred to nitrocellulose membrane. On
incubation with generated mAb, a band was detected
between 15 and 20 kDa, after the chemiluminescent
detection of anti-RANK IgG (Fig. 4).
Osteoclast Generation and Confirmation by TRAP
Staining
Osteoclasts were generated by dosing the RAW264.7 cells
with RANKL and MCSF. The staining for TRAP is a
technique commonly used to visualize osteoclasts. The
principle behind staining of TRAP involves the use of
napthol AS phosphates in conjunction with fast garnet
GBC salts for the detection of acid phosphatase. This
diazonium fast garnet GBC salt was selected because it
couples rapidly at acid pH, forming insoluble dye deposits.
Napthol AS-BI, released by enzymatic hydrolysis, couples
immediately with fast garnet GBC salt, resulting in the
1 2        3        5 6 4







Fig. 2 SDS-PAGE analysis of
mAb-sCTconjugate and unconju-
gated antibody. A protein band
above 150 kDa was seen for
mAb-sCTconjugate in
non-reduced SDS-PAGE analysis.
Some bands above 50 kDa as well
as 25 kDa were observed for the
conjugate in reduced SDS PAGE.
Lane 1: unconjugated antibody
(non-reducing condition),
Lane 2: mAb-sCTconjugate (non-
reducing), Lane 3, 6:
standard marker, Lane 4:
mAb-sCTconjugate (reducing),




Fig. 3 (a) ELISA conducted on RANK receptor-coated plate. The optical
density was seen to be proportional with the concentration of anti-RANK
antibody. (b) ELISA of the mAb-sCT conjugate where anti-Calcitonin
secondary antibody reagent was used to detect immobilized Calcitonin
residues that were part of the primary anti-RANK conjugates and that
were binding to the RANK-coated wells. Optical density for mAb alone
was negligible as it did not have calcitonin to be detected by anti-calcitonin
antibody. Similarly, OD for sCT-PEG was also significantly low as it did not
have anti-RANK antibody to bind to RANK-coated plate.
Universal Osteoclast Drug Targeting Platform 1137formation of insoluble maroon deposits at sites of
activity. Tartaric acid was used in order to demonstrate
the presence of tartrate-resistant acid phosphatase.
Hence, cells containing tartrate-sensitive acid phospha-
tase are devoid of activity, and only the cells containing
tartrate acid-resistant phosphatase show maroon dye
deposits at the sites of activity. Staining confirmed that
the presence of TRAP-positive multinucleated osteoclast-
like cells was limited to those wells dosed with exogenous
M-CSF and RANKL, under the cell culture conditions
described (Fig. 5).
Immunocytochemistry
Confocal microscopy confirmed that the anti-RANK
receptor mAb staining (green color) was limited to
surface receptors present on osteoclastic precursors as
well as mature osteoclast-like cells (Fig. 6a). Counter-
staining with DAPI (blue color) confirmed the multinu-
cleated phenotype of osteoclast-like giant cells. Nucleoli
were also witnessed in the images. There was no
demonstrable fluorescent fluorescein isothiocyanate
(FITC) staining in negative control slides (Fig. 6b and c).
A commercially available anti-RANK mAb was used as a
positive method control to confirm that RAW 264.7
osteoclastic precursors as well as mature osteoclast-like
cells indeed stained for surface RANK receptors using
immunocytochemistry.
TRAP Activity Assay
RAW 264.7 cell cultures treated with exogenous RANKL
and MCSF showed a 9.9-fold increase of TRAP activity
compared to controls without cytokine treatment. We
found that the release of this osteoclast-associated enzyme
was potently inhibited by our mAb-sCT conjugate (and by
our unconjugated mAb alone), as compared to sCT alone
(Fig. 7). We measured a 5.47-fold decrease in TRAP
activity after treatment with mAb-sCT conjugate. Also, the
conjugate showed a 2.82-fold greater inhibition of TRAP
compared to sCT treatment alone.
In Vitro Mineral Resorption Assay
The osteoclast-like cells generated on Osteologic® calcium
phosphate-coated culture wells were shown to be capable of
resorbing the immediate calcium phosphate layer surround-
ing them. That result was in direct contrast to precursor
RAW 264.7 cells (cultured in the absence of M-CSF and
RANKL) that were shown not to affect the calcium
phosphate coating in any manner. Osteoclast-like cell
cultures treated with the mAb-sCT conjugate, or mAb
alone, demonstrated a significant inhibitory effect on the
resorptive ability of the osteoclast-like cells, as measured by
the conservation of calcium phosphate layer on the
Osteologic® slide. The integrated density value (IDV) of
the remaining calcium phosphate layer for the culture
treated with the mAb-sCT conjugate was significantly
greater than that treated with sCT alone (Fig. 8).
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Fig. 4 Western Blot Analysis: Lane 1: a band seen between 20 kDa and
15 kDa as a result of chemiluminescent detection of anti-RANK IgG. Lane
2: standard marker. RANK receptor (19.3 kDa) was electrophoresed on
10% SDS-PAGE. Protein was transferred to nitrocellulose membrane
which was blocked with 5% skim milk, followed by the incubation with
anti-RANK mAb. Reaction was detected by using GAM-HRPO, and the
membrane was developed using ECL reagent and exposure to X-ray film.
Fig. 5 Multinucleated TRAP-positive osteoclast was observed by TRAP
staining. RAW 264.7cells, a murine macrophage-like osteoclast precursor
line, were stimulated with 50 ng/ml RANKL and 25 ng/ml MCSF for
osteoclast generation.
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To test for potential cytotoxic effects of our mAb and/or
mAb-sCTconjugate,wetestedRAW264.7cellviabilityusing
the MTT assay. Anti-RANK monoclonal antibody, mAb-
sCT conjugate andsCT showednodemonstrable cytotoxicity
at the concentrations tested (up to 200 nM), as measured by
the absorbance of formazan solution formed after 4 h
incubation (Fig. 9). Thus, the viability of these cells was not
perturbed by our mAb and/or conjugate treatments.
In Vitro Bioactivity of mAb-sCTand Calcitonin
Receptor Binding Affinity
Using an in vitro competitive binding assay, cAMP activity
was determined in TD47 breast cancer cells known to
contain the calcitonin receptor. The assay confirmed that
sCT and the mAb-sCT conjugate were capable of
stimulating cAMP production after binding the calcitonin
receptor. The significantly lower absorbance values mea-
sured (due to the competitive nature of the assay) indicated
the ability for sCT and/or mAb-sCT to generate intracel-
lular cAMP in the presence of a phosphodiesterase
inhibitor. Conversely, the mAb-treated and control wells
exhibited negligible intracellular cAMP generation, and,
accordingly, high absorbance values in the competitive
binding assay were observed (Fig. 10).
DISCUSSION
Osteoclasts are the only cells capable of resorbing miner-
alized bone. However, current antiresorptive therapies do
not specifically target the osteoclast cell and elicit systemic
side effects in cells other than osteoclasts. For example, the
development of duodenal ulcers, gastric erosions and
potentially even osteonecrosis of the jaw or catastrophic




Fig. 6 (a) Confocal images of immunocytochemistry performed with
anti-RANK mAb which detected RANK receptors, the surface receptors
present on the osteoclasts as well as osteoclast precursors. Counter-
staining with DAPI showed the multinucleation in osteoclasts. (b) Confocal
image of immunocytochemistry for osteoclast cell culture omitting primary
antibody, as a negative control. (c) Confocal image of immunocytochem-
istry for osteoblast-like MG-63 cell line as a negative control. The MG-63
cell line does not express RANK receptors.
Fig. 7 Tartrate-resistant acid phosphatase (TRAP) activity assay. mAb-sCT
conjugate showed an inhibitory effect on TRAP activity, an important
marker of osteoclasts. RAW: cells cultured in media with 0 ng/ml
RANKL+0 ng/ml MCSF; OC: cells cultured in media with 50 ng/ml
RANKL+25 ng/ml MCSF; mAb-sCT: cells cultured in media with
50 ng/ml RANKL+25 ng/ml MCSF+100 nM conjugate; mAb: cells
cultured in media with 50 ng/ml RANKL+25 ng/ml MCSF+100 nM
mAb; sCT: cells cultured in media with 50 ng/ml RANKL+25 ng/ml
MCSF+100 nM sCT . * P<0.05 versus OC; ** P<0.05 versus sCT.
No statistically significant difference was observed between naked
antibody and the conjugate.
Universal Osteoclast Drug Targeting Platform 1139associated with differing classes of bisphosphonates, the
most commonly prescribed medication for osteoporosis
(23). Estrogen hormone replacement therapy stimulates
uterine and breast tissue, which predisposes the patient to
neoplastic disease (24). Leg muscle cramps, joint aches and
deep vein thrombosis has been associated with selective
estrogen receptor modulator therapy (25). Similarly, con-
ventional salmon calcitonin has shown limitations in
antiresorptive efficacy, likely in part because of poor
bioavailability to bone cells and the undesired uptake of
the drug by calcitonin receptors present in tissues other
than bone (26,27).
Since the pharmacological arrest of the osteoclast is
the mainstay of treating systemic bone loss, drug delivery
strategies that target the osteoclast directly would provide
a potential therapeutic advantage at reducing systemic
bone loss by selectively delivering an antiresorptive drug
“cargo” to the osteoclast. Antibodies are renowned for
their exquisite specificity of target recognition and
generate highly selective outcomes following their sys-
temic administration. As the RANK receptor is predom-
inantly expressed on the surface of mature osteoclasts, we
hypothesized that an anti-RANK antibody would facili-
tate an effective osteoclast targeting platform for the
delivery of antiresorptive drug directly to the resorbing
bone cells.
Salmon calcitonin, a single chain polypeptide hormone
consisting of 32 amino acids, was chosen as a “model” drug
for this study, as sCT therapy is known to inhibit and/or
slow osteoclast-mediated resorptive bone loss, whilst posi-
tively influencing osteoinduction and bone formation (28).
Hence, we designed a conjugative strategy whereby
calcitonin would be coupled to an antibody directed
predominantly against osteoclast-specific receptors, in order
to impart osteoclast specificity to the attached calcitonin
“cargo.” Delivery of sCT to the osteoclast cells by virtue of
an antibody-mediated targeting platform would ensure that
the calcitonin drug remained primarily localized to bone
tissue after systemic administration. This would directly
contrast with the passive interaction of calcitonin with other
tissues that express the calcitonin receptor, such as kidneys,
liver, lungs, spleen, heart and thyroid. Hence, a delivery
system capable of improving sCT targeting and localization
to osteoclast could have a potential to positively impact
Fig. 8 Demonstration of resorption pit formation on osteologic substrate
plate. After 7 days of culture, adherent cells were removed, and integrated
density value of the remaining osteologic layer was calculated using
alphaimager densitometer. RAW: cells cultured in media with 0 ng/ml
RANKL+0 ng/ml MCSF; OC: cells cultured in media with 50 ng/ml
RANKL+25 ng/ml MCSF; mAb-sCT: cells cultured in media with
50 ng/ml RANKL+25 ng/ml MCSF+100 nM conjugate; mAb: cells
cultured in media with 50 ng/ml RANKL+25 ng/ml MCSF+100 nM
mAb; sCT: cells cultured in media with 50 ng/ml RANKL+25 ng/ml
MCSF+100 nM sCT. *P<0.05versus OC; ** P<0.05versus sCT. No
statistically significant difference was observed for antibody versus
conjugate and antibody versus calcitonin.
Fig. 9 In vitro cytotoxicity of mAb, mAb-sCT & sCTon RAW 264.7 cells
was determined by MTTassay. No demonstrable cytotoxicity was seen as
measured by the absorbance of formazan solution formed after 4 h
incubation with compounds, compared to that seen with untreated
media. Samples were not statistically significant compared to the control at
all concentrations.
Fig. 10 Calcitonin receptor binding affinity and in vitro bioactivity of mAb-
sCT determined by using intracellular cAMP stimulation in human T47D
cells. 50,000 cells/well were cultured for 2 days in 48-well plates in RPMI
1,640 containing insulin, and the phosphodiasterase activity was blocked
using 3-IBMX. Cells were then treated with 100 nM of mAb, mAb-sCT
conjugate and sCT, and the generated cAMP was assayed by cAMP ELISA.
* P<0.05 versus all other cultures.
1140 Newa et al.sCT therapy, whilst reducing the drug concentration in
non-bone loci containing the calcitonin receptors.
Using hybridoma technology, we generated and
characterized a specific monoclonal antibody against
recombinant human RANK receptor, and chemically
coupled synthetic sCT to that anti-RANK mAb carrier.
We further PEGylated sCT in the process of conjugation
by using the polymer polyethylene glycol, which is known
to improve the major disadvantages of conventional sCT
by increasing solubility, stability, and efficacy and
reducing the immunogenecity. It has also been estab-
lished that PEGylation enhances the enzymatic stability
of calcitonin (29) against proteolysis, by forming an
effective shield against degradative enzymes (30)w h i l s t
improving its efficacy in vivo by increasing molecular size,
thus contributing to reduced renal filtration (31) allowing less
frequent administration (32).
The synthesized bio-conjugate was initially characterized
using SDS-PAGE analysis and ELISA. Protein band above
150 kDa was observed for the conjugate under non-
reducing condition of SDS-PAGE analysis, and some bands
were seen above 50 kDa and 25 kDa under reducing
condition, thus suggesting that conjugation of PEGylated
sCT with mAb had occurred. An ELISA further verified
the successful conjugation of sCT to our mAb, as the anti-
calcitonin secondary antibody reagent would only detect
immobilized calcitonin residues that were part of the
primary anti-RANK conjugates that were binding to the
RANK-coated wells of the ELISA plate. A slight signal was
observed for PEGylated sCT, and we assume that this
could be due to the reaction of thiol reactive MAL
functional group of PEGylated sCT with the free thiol
group in BSA used as a blocking agent. In the case of
conjugate, such MAL groups were utilized in the reaction
with free thiol groups generated in antibody.
In order to verify the efficacy of mAb-sCT conjugates,
we employed in vitro osteoclast-like cell cultures. It is well
established that osteoclasts are derived from cells of the
monocyte/macrophage lineagea n da r ef o r m e da f t e rt h e
cellular fusion of their mononuclear precursors (33).
Hence, we utilized the RAW 264.7 cell line that can be
differentiated in vitro into osteoclast-like cells after expo-
sure to M-CSF and RANKL cytokines. RANKL is the
essential factor necessary for osteoclast differentiation,
whilst M-CSF (also known as CSF-1) has also been
identified as an essential factor necessary to initiate
osteoclastogenesis (34) .T h em a i nr o l eo fM - C S Fi st oa c t
as a survival factor for osteoclast precursor cells and to
induce the expression of the RANK receptor for stimulation
by the RANKL.
Immunocytochemistry confirmed the osteoclast targeting
potential of our generated anti-RANK mAb in vitro.
Fluorescent staining of our anti-RANK mAb was specifi-
cally localized to cellular surface receptors. DAPI staining
showed the successful generation of multinucleated
osteoclast-like cells. No demonstrable FITC staining was
seen for negative controls. These results support the
evidence that osteoclast-like cells generated from RAW
264.7 precursor cells express the RANK receptor, and our
generated anti-RANK antibody can be used as a potential
osteoclast targeting platform. The successful generation of
osteoclast-like cells was also confirmed by TRAP staining,
which confirmed multinucleated cells with maroon-colored
dye deposits due to the presence of TRAP, the enzyme that
has been used as a marker of osteoclast function for more
than 20 years (35).
To determine the in vitro efficacy of the anti-RANK
mAb-sCT conjugate on osteoclast activity, we quantified
osteoclast activity using a spectrophotometric total culture
TRAP activity assay and a mineral resorption assay. TRAP
has been shown to be a specific and sensitive indicator of
bone resorption (36) and contributes to the intracellular
processing of primary bone matrix degradation products
prior to its final release through the basolateral membrane
of resorbing osteoclast cells (37,38). Osteoclasts, as the
bone-resorbing cells of the body, further show the ability to
dissolve the mineralized inorganic phase of bone matrix
known as hydroxyapatite (39). We found that the use of our
conjugate in culture significantly reduced TRAP enzyme
activity as compared to sCT alone, and use of the mAb
alone also showed inhibition of TRAP enzyme activity.
Although the cause for this effect shown by our anti-RANK
antibody alone has not been tested, we speculate that in
binding the RANK receptor, the antibody may be
functioning as a receptor antagonist. That competitive
binding would interfere with the interaction of RANKL
with RANK, an essential step of osteoclast differentiation.
Nonetheless, further antiresorptive and/or anabolic effector
functions could be attributed with the development of a
targeted delivery strategy to osteoclast cell receptors. We
further evaluated if the mAb-sCT conjugate had an effect
on the ability of osteoclasts to resorb bone. We cultured
osteoclast-like cells on calcium phosphate-coated culture
plates in the presence of conjugate, antibody or sCT. We
found that both the conjugate and the mAb alone were
capable of significantly reducing the resorption of mineral
layer as compared to the sCT alone. Then, we performed
cyclic AMP assay to confirm that bioactivity of conjugated
calcitonin. Human breast carcinoma T47D cells known
to express the calcitonin receptor were used for this
purpose. Binding of sCT with its receptor activates
adenylyl cyclase, an enzyme responsible for the genera-
tion of cAMP. Our in vitro cAMP assay results confirmed
that the modification of sCT by conjugation did not
interfere with its ability to bind the calcitonin receptor
and trigger its biological activity. We measured the
Universal Osteoclast Drug Targeting Platform 1141conjugate to have increased activity over calcitonin alone,
and the exact reason for that effect is still not clear. It is
likely our conjugation strategy allowed one mole of
antibody to become conjugated with greater than one
mole of calcitonin. It has been reported that when IgG is
treated with a 10 molar excess of Traut’s reagent, 3-7
thiol groups are generated, which may result in the
attachment of 3-7 PEGylated calcitonin molecules per
molecule of IgG.
The results obtained so far have been quite encour-
aging from the generation of antibody and to the
synthesis and in vitro evaluation of the conjugate. The
conjugate and the antibody alone showed good efficacy in
TRAP activity inhibition and resorption pit assay. However,
cAMP assay showed that the conjugate served the purpose of
delivering active drug cargo. The conjugate showed the
ability to bind the calcitonin receptors and generate intracel-
lular cyclic AMP, thus showing an advantage over the
antibody alone.
With the advent of novel RANKL-scavenging antibody-
based antiresorptive strategies (such as Denosumab– Pro-
lia®, Amgen Inc.), it may further prove efficacious to target
the RANK receptor directly with an antibody, in order to
successfully antagonize receptor signaling and osteoclast
function. However, neither the “scavenging” nor “antago-
nist” motives of those antiresorptive strategies focus on the
targeted delivery of a given drug cargo (such as our anti-
RANK mAb-conjugate design) which would function as a
universal osteoclast targeting platform.
One potential limitation of our osteoclast targeting
platform remains that RANKL-RANK signaling is not
entirely restricted to osteoclasts and their precursors, but
is known to be involved in the regulation of other cell
types. Studies have that RANKL-RANK signaling con-
trols the development of lactating mammary glands in
pregnancy, with the highest levels being at day 15.5 in
mice (40,41). Several studies that looked at transgenic
Rankl-/- and Rank-/- mice found that there was a
complete absence of lymph nodes (42). This led to further
studies involving patients with an osteoclast-poor form of
t h ea u t o s o m a lr e c e s s i v eo s t e o p e t r o s i s( A R O ) ,w h e r et h e y
found the cause of the disease to be various mutations in
RANKL (43) .T h es a m er e s e a r c ht h e nf o u n dt h a tt h e s e
patients showed no palpable signs of lymph nodes, further
strengthening the theory that RANKL-RANK signaling is
involved in lymph node formation in humans. RANK is
further known to be expressed by monocyte/macrophages
and dendritic cells, specialized immune cells programmed
to capture and process antigens in the body and present
them to naïve T-cells (44). However, the targeting of drug
“cargo” to the RANK receptors of those cells may not
necessarily result in drug action with those cells if the
cargo is carefully chosen not to affect those cell types. For
example, it is highly unlikely for any cell (other than the
mature osteoclast) to express both the RANK receptor
and calcitonin receptor at the same time. Thus, the
Boolean “and/or” logic can be applied to the selection
of the differential cargo targeting to cellular phenotypes
expressing the RANK receptor at any given time. The
extent of this limitation remains to be fully determined,
however, should not necessarily preclude the further explora-
tionofRANKreceptortargetingstrategies,whichmayinturn
provide a more comprehensive understanding of RANK
signaling and crosstalk with other signaling pathways.
CONCLUSION
This study details the generation of an antibody-mediated
osteoclast-targeting platform. This drug-delivery strategy
may find utility as “a universal osteoclast-targeting plat-
form” in order to directly target and deliver antiresorptive
agents, anti-inflammatory agents, cathepsin K inhibitors,
disintegrins, H
+-ATPase inhibitors, and so on, directly to
osteoclast cells. We have shown this platform is capable of
being employed as an antiresorptive strategy, and our
efforts will now center on the in vivo evaluation of this
targeting strategy.
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